SCHEMBL5528059

SCHEMBL5528059

CCc1cccc(C(C)C)c1NC(=S)N(C)C1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.49
▸ ABCC1 P33527 3/20 0.47
▸ MAPT P10636 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ KMT2A Q03164 2/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KCNH2 Q12809 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538579 0.84 POLB (0.55) POLBABCC1MAPTLMNAKMT2A
SCHEMBL5527058 0.84 POLB (0.55) POLBABCC1MAPTLMNAKMT2A
SCHEMBL11416982 0.79 ALOX12 (0.56) LMNAKMT2AALDH1A1GAASMN1; SMN2
SCHEMBL5538230 0.73 HTT (0.50) LMNAKMT2ASMN1; SMN2MEN1HTT
SCHEMBL5530274 0.72 ATM (0.54) POLBABCC1LMNAKMT2ANPC1
SCHEMBL8689693 0.71 HTT (0.44) LMNAKMT2ASMN1; SMN2CYP2C19MEN1
SCHEMBL25197276 0.71 HTT (0.62) MAPTLMNAKMT2AALDH1A1GAA
SCHEMBL8582040 0.71 HTT (0.43) ABCC1LMNAKMT2AALDH1A1SMN1; SMN2
SCHEMBL8689690 0.70 NLRP3 (0.42) LMNAKMT2ASMN1; SMN2MEN1HTT
SCHEMBL13925886 0.70 SMN1; SMN2 (0.53) LMNAKMT2ASMN1; SMN2MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 POLB 4518/4885ABCC1 2977/4885MAPT 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback